Literature DB >> 33464167

Group I p21-activated kinases in leukemia cell adhesion to fibronectin.

Kateřina Kuželová1, Adam Obr1, Pavla Röselová1, Dana Grebeňová1, Petra Otevřelová1, Barbora Brodská1, Aleš Holoubek1.   

Abstract

P21-activated kinases (PAK) regulate processes associated with cytoskeleton dynamics. PAK expression in leukemia cells was measured on protein and mRNA levels. In functional assays, we analyzed the effect of PAK inhibitors IPA-3 and FRAX597 on cell adhesivity and viability. PAK2 was dominant in cell lines, whereas primary cells also expressed comparable amount of PAK1 transcription isoforms: PAK1-full and PAK1Δ15. PAK1Δ15 and PAK2 levels correlated with surface density of integrins β1 and αVβ3. PAK1-full, but not PAK2, was present in membrane protrusions. IPA-3, which prevents PAK activation, induced cell contraction in semi-adherent HEL cells only. FRAX597, which inhibits PAK kinase activity, increased cell-surface contact area in all leukemia cells. Both inhibitors reduced the stability of cell attachment and induced cell death.

Entities:  

Keywords:  AML; ECIS; IRM; PAK; acute myeloid leukemia; cell adhesion

Mesh:

Substances:

Year:  2021        PMID: 33464167      PMCID: PMC7834095          DOI: 10.1080/19336918.2021.1872760

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  51 in total

1.  Expression of constitutively active alpha-PAK reveals effects of the kinase on actin and focal complexes.

Authors:  E Manser; H Y Huang; T H Loo; X Q Chen; J M Dong; T Leung; L Lim
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

Review 2.  Structure, biochemistry, and biology of PAK kinases.

Authors:  Rakesh Kumar; Rahul Sanawar; Xiaodong Li; Feng Li
Journal:  Gene       Date:  2016-12-19       Impact factor: 3.688

3.  Computational insight into the mechanisms of action and selectivity of Afraxis PAK inhibitors.

Authors:  Di Han; Huiqun Wang; Wei Cui; Beibei Zhang; Bo-Zhen Chen
Journal:  Future Med Chem       Date:  2020-02-17       Impact factor: 3.808

4.  Tumor promoter and fibronectin induce actin stress fibers and focal adhesion sites in spreading human erythroleukemia (HEL) cells.

Authors:  M Järvinen; J Ylänne; T Vartio; I Virtanen
Journal:  Eur J Cell Biol       Date:  1987-10       Impact factor: 4.492

5.  Pak1 and Pak2 mediate tumor cell invasion through distinct signaling mechanisms.

Authors:  Salvatore J Coniglio; Salvatore Zavarella; Marc H Symons
Journal:  Mol Cell Biol       Date:  2008-04-14       Impact factor: 4.272

6.  Differential effects of PAK1-activating mutations reveal activity-dependent and -independent effects on cytoskeletal regulation.

Authors:  J A Frost; A Khokhlatchev; S Stippec; M A White; M H Cobb
Journal:  J Biol Chem       Date:  1998-10-23       Impact factor: 5.157

7.  Endothelial cell retraction is induced by PAK2 monophosphorylation of myosin II.

Authors:  Q Zeng; D Lagunoff; R Masaracchia; Z Goeckeler; G Côté; R Wysolmerski
Journal:  J Cell Sci       Date:  2000-02       Impact factor: 5.285

8.  Dependence of acute myeloid leukemia on adhesion within the bone marrow microenvironment.

Authors:  Pamela S Becker
Journal:  ScientificWorldJournal       Date:  2012-01-04

9.  JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component.

Authors:  Xujun Liu; Wenzhe Si; Xinhua Liu; Lin He; Jie Ren; Ziran Yang; Jianguo Yang; Wanjin Li; Shumeng Liu; Fei Pei; Xiaohan Yang; Luyang Sun
Journal:  Mol Cancer       Date:  2017-11-29       Impact factor: 27.401

Review 10.  Rho GTPases: Anti- or pro-neoplastic targets?

Authors:  I Zandvakili; Y Lin; J C Morris; Y Zheng
Journal:  Oncogene       Date:  2016-12-19       Impact factor: 9.867

View more
  1 in total

Review 1.  Recent advances on development of p21-activated kinase 4 inhibitors as anti-tumor agents.

Authors:  Yang Li; Qing Lu; Chenghu Xie; Yiming Yu; Ao Zhang
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.